Too few women who could benefit from PrEP are prescribed it in the U.S., despite its effectiveness at preventing #HIV infection. A new #JInfectDis perspective explains why & offers strategies to improve PrEP use among women. http://bit.ly/2mLfugi #IDSAJournals #EndHIVepidemic
And the @US_FDA Advisory committee voted against approving Descovy for PrEP because no data exists using this drug for PrEP in women. Does @GileadSciences believe that not studying a Descovy in women is correct? How was this gender disparity accepted? @RWalensky @Armstrws
